← boardnext 2029-07
LQDA
Liquidia Technologies, Inc.distress 1/10 · well-funded / low risk$87.33+0%today0% from 52w high
Lead: PAH and PH-ILD
Revenue
$133M
Liquidity
$223M
Runway
—
Shares 1y
+3%
Price & events
+112.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.3%
1D
+16.0%
1W
+17.9%
1M
+133.1%
3M
+115.2%
6M
+392.0%
1Y
+656.1%
2Y
+3450.0%
5Y
+2811.0%
All
Overview
- Market Cap
- $7.77B
- Volume
- 168.31K
- 52 Week Range
- $14.09 – $87.33
- Total Shares
- 88.93M
- Float Shares
- 62.34M
- Short %
- 18.41%
- % Held by Insiders
- 12.70%
- % Held by Institutions
- 70.63%
- RVOL
- 0.08x
- Beta
- 0.55
Pipeline stages · 1 programs
L606
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-07 Estimated 50% readout ~2029-09-14 | Phase 3 | L606 | Pulmonary Hypertension Due to Lung Disease (Disorder) | — | recruiting |
Catalyst news & presentations · 10
- 2026Guided 40%trial initiationsecondaryYUTREPIA · Support investigator-initiated trial of YUTREPIA combined with WinrevairSEC 8-K
- 2026Guided 40%readoutYUTREPIA · Complete ASCENT open-label study evaluating 52 weeks of treatment in PH-ILD patientsSEC 8-K
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- January 14, 2026conferencedata presentationsecondaryLiquidia CEO presents at 44th Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- May 27, 2025conferencedata presentationsecondaryYUTREPIA · Webcast to provide commercial launch updateSEC 8-K
- May 24, 2025PDUFAPDUFAYUTREPIA (treprostinil) · PDUFA goal date for YUTREPIA NDA resubmissionSEC 8-K
- March 28, 2025filing acceptanceFiled (NDA/BLA)YUTREPIA (treprostinil) · FDA accepted NDA resubmission for YUTREPIASEC 8-K
- 2025-03-17partnershipSixth Amendment to Revenue Interest Financing Agreement with HealthCare Royalty for up to $100M additional financing, of which $25M funded at closing.SEC 8-K
- 2024-10-02partnershipL606 · Expanded exclusive license to include Europe, Japan, etc. and obtained rights to Pharmosa's next-generation nebulizers for L606SEC 8-K
- 2023-06-30partnershipPharmosa License AgreementSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $74 (-15% upside) · 8 analysts
- 2024-10-16ScotiabankSector Outperform
- 2024-10-03LifeSci CapitalOutperform
- 2024-08-23HC Wainwright & Co.Buy
- 2024-08-22NeedhamBuy
- 2024-08-20B of A SecuritiesBuy
- 2024-08-20HC Wainwright & Co.Buy
Competitors — PAH and PH-ILD
- none identified
Recent news
- 2026-07-23Liquidia Corp. (LQDA) Gains 8% Amid Patent Dispute Developments - GuruFocus
- 2026-07-23Liquidia director Stephen Bloch sells $6.28m in LQDA stock - Investing.com
- 2026-07-22Liquidia Corp (LQDA) director-linked fund sells 78,596 shares - Stock Titan
- 2026-07-21Liquidia Corp (LQDA:UQ): Stock Price, Quote and News - BNN Bloomberg
- 2026-07-20Is Liquidia Corp (LQDA) a Bargain After 3.6% Drop? GF Value Says Undervalued - GuruFocus
- 2026-07-20Is Liquidia Corp (LQDA) a Bargain After 3.6% Drop? GF Value Says Undervalued - GuruFocus
- 2026-07-20Liquidia Corp (NASDAQ:LQDA): An Affordable Growth Stock With Explosive Revenue Momentum and Reasonable Forward Valuation - ChartMill
- 2026-07-17Liquidia Corp (LQDA) Stock Up 6.2% and Still Undervalued -- GF S - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.